Renee
5 years ago
FRLI SEC Suspension "because of concerns about: (1) the adequacy and reliability of publicly available information concerning FRLI, including a press release issued by the company on April 15, 2019; and (2) unusual, unexplained market activity in the company’s stock, including certain transactions executed between April 26 through June 13, 2019."
https://www.sec.gov/litigation/suspensions/2020/34-88375.pdf
Order:
https://www.sec.gov/litigation/suspensions/2020/34-88375-o.pdf
enzymesarecool
5 years ago
Desparate Financing at Ridiculous Rates
The company just took out a loan at 20 percent discount plus 10 percent interest and the entire amount can be converted into shares at 20 percent discount to lowest two closing prices.
So, the company got 200,000. In a year they will owe 240,000 based on initial discount plus 20,000 interest for a total of 260,000 and the lender can convert that into about 320,000 worth of shares.
Does this sound like the kind of financing a company with any kind of solid business opportunity would do?
This thing is going to zero really quick. If you have shares, get out before this person converts and floods the market with millions of shares trying to get any money back.
Buyer and holder beware!!!
236T568
5 years ago
So....you are impressed by a PAID STOCK PROMOTION article?
Last week I received "Wall Street Daily Investor" special biotech/AI Investor Issue dated June 2019- in it, a lengthy article about this company that I found impressive and quite interesting. I happen to be a health and good nutritional follower and firm believer in customizing the system. Also a believer of AI and Biotech have a lot potential to contribute in this area.
According to what I read, what this company does is first of a kind, direct-to-consumer DNA analysis using the most powerful AI that measures 60 million genomic data points to precisely predict risk for developing diseases such as most cancers, diabetes, rheumatoid arthritis, and Crohn's Disease, as well as nutritional deficiencies that lead to disease.
This is interesting to me and I see here something of the future to individualizing medicine and the next important step in medicine. Now folks like me see the way traditional medicine being non individual in many ways and medicine dispensed merely on groups, age, and sex. That is not enough and a lot has to change in dispensing what kind of medicine, what dosage after knowing scientifically what happens to be one's DNA and the impact of one's specific unknown information. I have seen and suffered and finally rejected traditional medical imprecise approaches and the future of medicine will have to be based directly on one's specific DNA analysis and not general knowledge from large multitudes of people's data.
If all that I read is true, this company is an "avant-garde" of a better and brighter future. I intend to buy 1000 shares at the current price of $0.88, this Monday June 17, 2019.
The article's projected 12-28 month prices: S.T. (12 months) is $4.24;
M.T. (24 months) is $10.47; and L.T. (28 months) is $23.41
Nobody knows the future, let alone this company and it's future. I happen to be excited by such news and happy to spend this money, and more, in AI and Biotech endeavor and basically about these industries and the promises they hold in the health area. I happen to be also a gamer and (high?) risk taker. Been a high roller before my retirement and still enjoy being one! GLTA
JJ8
5 years ago
Last week I received "Wall Street Daily Investor" special biotech/AI Investor Issue dated June 2019- in it, a lengthy article about this company that I found impressive and quite interesting. I happen to be a health and good nutritional follower and firm believer in customizing the system. Also a believer of AI and Biotech have a lot potential to contribute in this area.
According to what I read, what this company does is first of a kind, direct-to-consumer DNA analysis using the most powerful AI that measures 60 million genomic data points to precisely predict risk for developing diseases such as most cancers, diabetes, rheumatoid arthritis, and Crohn's Disease, as well as nutritional deficiencies that lead to disease.
This is interesting to me and I see here something of the future to individualizing medicine and the next important step in medicine. Now folks like me see the way traditional medicine being non individual in many ways and medicine dispensed merely on groups, age, and sex. That is not enough and a lot has to change in dispensing what kind of medicine, what dosage after knowing scientifically what happens to be one's DNA and the impact of one's specific unknown information. I have seen and suffered and finally rejected traditional medical imprecise approaches and the future of medicine will have to be based directly on one's specific DNA analysis and not general knowledge from large multitudes of people's data.
If all that I read is true, this company is an "avant-garde" of a better and brighter future. I intend to buy 1000 shares at the current price of $0.88, this Monday June 17, 2019.
The article's projected 12-28 month prices: S.T. (12 months) is $4.24;
M.T. (24 months) is $10.47; and L.T. (28 months) is $23.41
Nobody knows the future, let alone this company and it's future. I happen to be excited by such news and happy to spend this money, and more, in AI and Biotech endeavor and basically about these industries and the promises they hold in the health area. I happen to be also a gamer and (high?) risk taker. Been a high roller before my retirement and still enjoy being one! GLTA
236T568
5 years ago
FRLI Letter to Shareholders filed in an 8K today with the SEC
https://www.sec.gov/Archives/edgar/data/1223533/000149315219008315/ex99-1.htm
EX-99.1 2 ex99-1.htm
Dear fellow shareholders,
The last several months have been very eventful for Frelii and I wanted to take the opportunity to bring you up to date on the excellent progress we have been making. We recently posted our quarterly financial statement, which can be viewed at www.frelii.com. We’ve entered into a relationship with our first customer, and we’ve continue to gain positive interest from legitimate media and investors.
In spite of many good announcements and positive milestones achieved, I also want to address a concern regarding our common stock.
The Frelii common stock is traded under the ticker symbol FRLI on the OTCQB Venture Market, which is designed for early stage and developing U.S. and international companies. It is part of OTC Markets Group Inc. (“OTC”).
On May 14, 2019 OTC informed us that they were seeing some unauthorized promotional activity, including newsletters, emails and online items highlighting our common stock. These pieces included wildly speculative claims such as “hypothetical” graphs showing the stock increasing by nearly 1,000% over the next several months and other exaggerations, false assertions and incomplete and misleading statements targeted at potential investors. In addition, we noted that the Company has been included on some stock “watch lists” or buy/sell recommendation lists that are published by third parties, including bloggers who are in no way affiliated with the Company.
It is regretful that our good name and the positive progress we are making have been tarnished by those who do not share the same values of honesty and transparency that we do, including their posting of unauthorized promotional content.
Recently, as a result of this type of third-party unauthorized online promotional content, our symbol was flagged for “stock promotion” and was placed under subsequent trade restrictions, which we hope to have lifted soon. We posted a press release on May 16, entitled, “Frelii, Inc. Issues Statement Regarding Unauthorized Promotional Activity Involving Its Common Stock”, to ensure the market and our loyal shareholders, customers and partners that we in no way engaged in or knowingly allowed anyone to post unauthorized promotional content.
I want to again reiterate, in no uncertain terms, that FRLI does not have and has never had any association with the people and the organizations that have conducted these promotional activities. They have had no access to non-public information regarding the Company or its future plans. We further advise that anyone interested in Frelii should not buy or sell any shares based upon contact with any party that solicits prospective investors or makes claims about the Company that have not been publicly disclosed by the Company itself.
This content was not commissioned, sanctioned or paid for by the Company and we had no editorial control over any of those materials. We have conducted inquiries of management and known shareholders, to the very best of our knowledge, neither the Company, nor any of its officers, directors, IR team or any controlling shareholders have been involved with the creation or distribution of promotional newsletter emails or online content that make exaggerated or misleading claims related to the Company and its securities.
Over the past months FRELII has announced legitimate news properly and exercised appropriate PR and IR efforts to ensure all of our news and market-facing statements created millions of impressions across legitimate news and Market information sites. We’ve received positive coverage in legitimate business and industry outlets, and our brand continues to gain popularity through the accurate information Frélii is responsible for making available to the public and shareholders.
We pride ourselves on making it easy to access legitimate information about our company and business activities. We frequently update our website at www.frelii.com with all legitimate news, company statements and legitimate media coverage. We encourage shareholders, customers, partners and potential investors to return frequently to learn about us and the advancements we are making through our press releases, our filings and disclosures made with the SEC (through the EDGAR Database) and OTC Markets Group.
Another important point is that this unauthorized promotional activity coincided with a higher than average trading volume and volatility in our stock price. We believe that the promotion may have impacted the market activity, but our stock price was on an upward trajectory primarily due to other factors including the fact that we announced the boarding of our first revenue-generating client Optivida on May 1, 2019 (see that press release here), and we have more on the way. We also have growing awareness by legitimate industry media and our solutions align with the cannabis/CBD space, which is an industry that is attracting a great deal of investor interest.
We have been working diligently for the past eight months to launch the company and introduce our AI technology and new products to the market (including the CBD industry) through traditional IR and PR efforts, participation in industry conferences and executing on our business growth plans. We also recently added three new members to our executive management group who bring powerful and deep expertise across all functional areas of the organization to round out our leadership team. These are in addition to Jayson Uffens, who is one of the industry’s finest CTOs in charge of our unique technology.
I believe these actions, coupled with our strategic business plans, will prove to generate strong and sustainable growth opportunities for Frelii and its shareholders in the coming months and foreseeable future.
We will continue to address the challenges we face in the wake of the unauthorized activities and we will always keep our investors and shareholders aware of legitimate and credible news from Frelii. Thank you for your continued support.
Sincerely,
Ian Jenkins, CEO
Bogaloo
5 years ago
Penny stock researchers are the one causing this issue, I have the emails if proof is needed, they have sent out numerous email regarding FRLI.
This was just announced by FRLI
On May 14, 2019 OTC informed us that they were seeing some unauthorized promotional activity, including newsletters, emails and online items highlighting our common stock. These pieces included wildly speculative claims such as "hypothetical" graphs showing the stock increasing by nearly 1,000% over the next several months and other exaggerations, false assertions and incomplete and misleading statements targeted at potential investors. In addition, we noted that the Company has been included on some stock "watch lists" or buy/sell recommendation lists that are published by third parties, including bloggers who are in no way affiliated with the Company.
It is regretful that our good name and the positive progress we are making have been tarnished by those who do not share the same values of honesty and transparency that we do, including their posting of unauthorized promotional content.
Recently, as a result of this type of third-party unauthorized online promotional content, our symbol was flagged for "stock promotion" and was placed under subsequent trade restrictions, which we hope to have lifted soon. We posted a press release on May 16, entitled, "Frelii, Inc. Issues Statement Regarding Unauthorized Promotional Activity Involving Its Common Stock", to ensure the market and our loyal shareholders, customers and partners that we in no way engaged in or knowingly allowed anyone to post unauthorized promotional content.
I want to again reiterate, in no uncertain terms, that FRLI does not have and has never had any association with the people and the organizations that have conducted these promotional activities. They have had no access to non-public information regarding the Company or its future plans. We further advise that anyone interested in Frelii should not buy or sell any shares based upon contact with any party that solicits prospective investors or makes claims about the Company that have not been publicly disclosed by the Company itself.
This content was not commissioned, sanctioned or paid for by the Company and we had no editorial control over any of those materials. We have conducted inquiries of management and known shareholders, to the very best of our knowledge, neither the Company, nor any of its officers, directors, IR team or any controlling shareholders have been involved with the creation or distribution of promotional newsletter emails or online content that make exaggerated or misleading claims related to the Company and its securities.
squidink
6 years ago
Today could be a defining moment in your life
Dear subscriber,
Two weeks ago, after a long hiatus, I sent you a stock tip which I believed would produce huge gains.
I was wrong. It was one of those rare ones that represent 1-2% of all my picks which severely underperforms.
The good news is that this has NEVER happened twice in a row. I am 1000% confident in the stock I have to tell you about today.
I made extremely sure of that because I want to redeem myself. I want to make you a fortune. I want you to be happy and thank me later.
I want to talk to you about a stunning breakthrough in artificial intelligence that is set to disrupt the entire world.
A.I. has the power to precisely predict whether a person’s future holds the potential to develop deadly diseases and sickness – threatening maladies such as diabetes, or cancers of the prostate, breast, lung, ovaries, and colon.
But, only one young Utah-based company has this early-warning, disease-predicting A.I.
That market could be vast because the A.I. is aimed squarely at consumers. Because of that, shares in the Utah-based company behind the A.I. could soar.
A.I. won’t let people cheat death – but this advanced technology delivers a first alert that can help people take steps to stave off diseases.
That’s because the advanced A.I. technology uses a small sample that contains DNA, then the A.I. delves deep into genetic makeup to precisely predict a person’s future risk of developing serious diseases or health complications.
The A.I.’s clear implication for dramatically bettering human lives is why investors need to move now on a still-under-the-radar opportunity with Frélii, Inc. It trades under the symbol FRLI
There’s nothing like it on the market now.
Moreover, while there is a lively direct-to-consumer DNA testing market, Frélii's sophisticated A.I. is a radical advance compared to commonplace DNA tests.
The difference is, other companies test DNA to help people discover their ancestral roots. But, Frélii's A.I. is on the vanguard of a new field called precision genomics.
FRLI is spearheading the precision genomics direct-to-consumer market because its A.I. analyzes 60 million genomic data points. That’s a whopping 10 times greater than other DTC DNA testing companies, which only analyze about 6 million data points.
Because of the massive amount of genomic data that the A.I. generates, Frélii's clients can now create new types of personalized lifestyle and healthcare strategies.
These personalized action plans can range from disease prevention, to improved nutrition, to determining the most effective drugs to treat medical problems, to advice on the most effective diets and exercise. The A.I. will even make personal grocery shopping lists.
There’s huge profit potential in unlocking secrets hidden deep in DNA.
In short, Frélii's precision genomics unlocks the door to a radical new form of healthcare – personalized healthcare based on specific individual genomic data.
It means a woman with the BRAC/1 gene variant that could cause deadly ovarian cancer has advanced warning of a cancer that is hard to detect unless doctors know what they are looking for.
It’s why ovarian cancer is deadly. Women may have no symptoms or just mild symptoms until the disease is in an advanced stage.
Using Frélii's A.I., women can make a plan with their doctors that includes early detection of precancerous tissue before it turns into a cancer that spreads through the body. The sooner ovarian cancer is found and treated, the better the chances are for recovery.
The same could hold true for prostate cancer, which is often caused by a BRAC/1 or BRAC/2 gene mutation.
Prostate cancer is the second leading cause of cancer death in men in the United States. The average age of detection is 66 years old.
So, advanced knowledge could encourage earlier testing in men who have the gene mutation.
The A.I megatrend is disrupting the health supplement market.
Frélii's A.I. has also taken another huge step forward in personalized individual health strategies.
That’s because poor nutrition plays an outsized role in causing disease, and its root cause could be hidden deep in DNA. The search for genetic nutrition problems even has a name – nutrigenomics.
After deep-diving into DNA, Frélii's A.I. uses nutrigenomic data to develop individual diet and nutrition plans that optimize health.
Frélii goes as far as stocking a huge number of nutritional supplements it can sell to its clients to optimize their nutrient balance.
So, if you are deficient in Vitamin D, it can tell.
In fact, it can tell by how much, just from your individual DNA.
If you have too much Vitamin C, it can tell.
And, it can provide you with the right amount, for your individual needs.
This will be the supplement megatrend that changes the way the world takes supplements.
A Potential Windfall for Shareholders
After running the numbers – and examining the company closely – I feel that FRLI is a one-of-a-kind company with a competitive advantage.
With that said, as I did with my readers, I am recommending Frélii, Inc. (FRLI) to you because it’s the rare young company that could actually disrupt a mature marketplace.
The company is actively working on spreading its technologies and just a few weeks ago FRLI’s CEO had a face-to-face meeting with Canada’s prime minister Justin Trudeau.
FRLI could enter the Cannabis business as a top player by analyzing consumers’ DNA and suggesting for them the perfect dosage and strain of plant that they need to use for the desired result.
This $1.60 stock could be trading as high as $20 by the end of the summer.
I have never seen a company with as much potential as FRLI.
I highly recommend you buy shares as soon as possible before this sleeping giant’s stock price rises thousands of percent.
This is one of the best BUY AND HOLD stocks I have seen in my entire life as an analyst.
In my opinion, it is the Uber of the medical industry. A small company, rising out of no-where in Utah and that could change how the average human interacts with his/her personal DNA forever.
A $5,000 investment into FRLI could make you a millionaire in a couple of years and could easily allow you to quadruple in the next 4-6 weeks.
ACT NOW AND BUY SHARES OF THIS HIDDEN GEM BEFORE THE MASSES GET AHOLD OF IT
Sincerely,
Kelvin Powell
Editor / PennyStockProPicks.com
© 2019 | PennyStockProPicks.com | All Rights Reserved.
If you would like to unsubscribe, please click on this link
Unsubscribe
This message was sent to santoalbanese@gmail.com from info@PennyStockProPicks.com
PennyStockProPicks.com
60 Kings Lane
Fayetteville, NC 28307
News
Market Data
Register for streaming realtime charts, analysis tools, and prices.
Ask ADVFN Intelligence (AI)
willlbone
5 years ago
dshade
5 years ago
bell345
6 years ago
Dr. Steve Brule
6 years ago
